Jason B. Daly's most recent trade in Amneal Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 22,000 Class A Common Stock done at an average price of $9.1 . Disclosure was reported to the exchange on Aug. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 12 Aug 2025 | 22,000 | 10,606 (0%) | 0% | 9.1 | 199,100 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.73 per share. | 05 Mar 2025 | 46,936 | 32,606 (0%) | 0% | 8.7 | 409,751 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.88 per share. | 05 Mar 2025 | 43,064 | 79,542 (0%) | 0% | 8.9 | 382,408 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 194,064 | 194,064 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 97,032 | 97,032 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 90,580 | 133,644 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 90,580 | 0 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 38,226 | 53,928 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 38,226 | 76,453 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 107,640 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 35,879 | 138,185 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 31,338 | 102,306 (0%) | 0% | 8.8 | 274,521 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 22,645 | 22,645 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 22,645 | 22,645 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 03 Mar 2025 | 15,579 | 122,606 (0%) | 0% | 8.8 | 137,718 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 10,864 | 43,064 (0%) | 0% | 8.8 | 95,169 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.76 per share. | 03 Mar 2025 | 6,943 | 15,702 (0%) | 0% | 8.8 | 60,821 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.40 per share. | 21 Nov 2024 | 13,665 | 0 (0%) | 0% | 8.4 | 114,786 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 8.61 per share. | 15 Nov 2024 | 43,657 | 13,665 (0%) | 0% | 8.6 | 375,887 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 287,038 | 287,038 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 143,519 | 143,519 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 38,226 | 114,679 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 38,226 | 68,186 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 22,645 | 37,126 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 22,645 | 45,290 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 03 Mar 2024 | 10,864 | 57,322 (0%) | 0% | 5.5 | 59,426 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.47 per share. | 03 Mar 2024 | 7,166 | 29,960 (0%) | 0% | 5.5 | 39,198 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 305,810 | 305,810 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 152,905 | 152,905 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 22,645 | 22,645 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 22,645 | 67,935 | - | - | Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.92 per share. | 03 Mar 2023 | 8,164 | 14,481 (0%) | 0% | 1.9 | 15,675 | Class A Common Stock |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 181,160 | 181,160 | - | - | Performance-Based Restricted Stock Units | |
| Amneal Pharma Inc (Class A) | Jason B. Daly | SVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 90,580 | 90,580 | - | - | Restricted Stock Units |